PEG-rhGH low dose
Phase 2Biologic
Changchun GeneScience Pharmaceutical Co., Ltd.PEG-rhGH low dose is one of 19 biologic programs targeting Turner syndrome. It is currently in Phase 2.
1
Indications
7
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Turner Syndrome
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Depo-Provera
Eli LillyPhase 3
Micronized Progesterone
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Approved
Estinyl
OOrganon and Co
Phase 3
R-Hgh
Merck & Co.Approved
Voxzogo
BioMarin PharmaceuticalPhase 2
Oestrogen
Novo NordiskApproved
Growth Hormone
PfizerPhase 2
Estradiol Valerate
BayerPhase 2
Oxandrolone
PPar Pharmaceutical, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
PrEP4 trials
Tics1 trial
Clinical Trial1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEG-rhGH low dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details